SHPG:NGS-Shire plc

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 179.20

Change

0.00 (0.00)%

Market Cap

USD 54.84B

Volume

1.00

Average Target Price

USD 204.33 (14.03%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Shire PLC is a biotech company. The Company is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines for patients with rare diseases and other select conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

N/A

USD 129.92B
GILD Gilead Sciences Inc.

N/A

USD 89.49B
BIIB Biogen Inc.

N/A

USD 67.98B
CELG Celgene Corporation

N/A

USD 60.41B
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD 49.76B
REGN Regeneron Pharmaceuticals Inc.

N/A

USD 45.33B
ALXN Alexion Pharmaceuticals Inc.

N/A

USD 26.11B
BMRN BioMarin Pharmaceutical Inc.

N/A

USD 17.39B
INCY Incyte Corporation

N/A

USD 16.69B
GRFS Grifols S.A.

N/A

USD 13.24B

ETFs Containing SHPG

AADR AdvisorShares Dorsey Wrig.. 0.00 % 1.25 %

N/A

USD 0.10B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.96% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.96% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 23.59% N/A N/A N/A N/A
Dividend Return 0.73% N/A N/A N/A N/A
Total Return 24.33% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 20.71% N/A N/A N/A N/A
Dividend Return 2.77% N/A N/A N/A N/A
Total Return 23.47% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -2.25% 43% F 27% F
Dividend Return -1.79% 42% F 26% F
Total Return 0.46% 22% F 13% F
Risk Return Profile  
Volatility (Standard Deviation) 23.23% 85% B 57% F
Risk Adjusted Return -7.69% 43% F 27% F
Market Capitalization 51.98B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 11.29 N/A N/A N/A N/A
Price/Book Ratio 1.49 N/A N/A N/A N/A
Price / Cash Flow Ratio 3.16 N/A N/A N/A N/A
Price/Free Cash Flow Ratio 15.42 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 13.03% N/A N/A N/A N/A
Return on Invested Capital 8.51% N/A N/A N/A N/A
Return on Assets 7.24% N/A N/A N/A N/A
Debt to Equity Ratio 37.25% N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.